30
Participants
Start Date
April 30, 2014
Primary Completion Date
October 10, 2016
Study Completion Date
October 10, 2016
Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
Epirubicin + Cisplatin + Fluorouracil
Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
Docetaxel + Ciclofosfamide
Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
Hospital Universitario Puerta del Mar, Cadiz
Hospital Universitario Reina Sofía, Córdoba
Hospital Universitario Juan Ramón Jimenez, Huelva
Complejo Hospitalario de Jaén, Jaén
Hospital Universitario Virgen Macarena, Seville
Hospital Universitario Virgen del Rocío, Seville
Hospital Universitario Nuestra Señora de Valme, Seville
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
OTHER